Developer docs
API playgroundTry for free, no card

Search company profiles

Arno Therapeutics

Full company profile

uuid0007c71

Namestring
Arno Therapeutics
Legal namestring
Arnothera
Websiteurl
arnothera.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Arno Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic products for the treatment of cancer patients. Founded in 2000 and headquartered in Parsippany, New Jersey, the company operates with a small team of 11-50 employees and trades publicly on the OTC pink market under the ticker ARNI. The company has raised approximately $61.4 million across four disclosed funding rounds between 2010 and 2016, drawing capital from biotech-focused institutional investors including Perceptive Advisors, Soros Fund Management, Pontifax, Bellco Capital, and UTA Capital.

The company's leadership team is anchored by Founder and Co-founder David M. Tanen, who also serves as Secretary and Director, and Chairman of the Board Arie Belldegrun. Historical financial disclosures from 2011-2015 reflect substantial operating losses consistent with a pre-commercial oncology developer, with no revenue line items populated across the disclosed period and EBITDA losses reported each year. The most recent capital activity dates to August 2016, and the company's continued listing on OTC pink (rather than a senior exchange) combined with the absence of post-2016 funding or commercial milestones in the input data suggests limited recent operational momentum.

Note on data quality: A significant portion of the aggregated input describes "Arnothera" (arnothera.com), a privately-operated Gold IRA educational website founded in 2023. This appears to be a distinct entity that has been conflated with Arno Therapeutics in the input. The biopharmaceutical interpretation has been used for this analysis based on the firmographics, leadership, financial, and funding data, which are internally consistent with a small public oncology developer.

Short descriptiontext

Arno Therapeutics is a publicly-traded biopharmaceutical company developing oncology therapeutics for cancer patients, headquartered in Parsippany, New Jersey, with 11-50 employees and a small-cap public listing on OTC pink.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology drug development, cancer therapeutics, biopharmaceutical products, precision oncology, clinical stage biotech
Industry2 codes
1Primary Care & General Medicine Pharmaceuticals
CodeHLAIAAAAPrimaryYes
2Urologic Oncology
CodeHLAKAOABPrimaryNo
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arno Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of cancer patients. The company's work centers on identifying and advancing targeted oncology drug candidates through preclinical and clinical development. Operations are focused on oncology R&D with the goal of addressing unmet medical needs in cancer treatment.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Arnothera is a financial information and education company that provides guidance on gold and precious metals IRAs for retirement planning. The core offerings consist of a Gold IRA (Precious Metals IRA) product that enables self-directed retirement accounts holding physical gold, silver, platinum, or palladium, supported by 401(k) to Gold IRA rollover/transfer services. These are complemented by financial education content including articles, worksheets, and guides covering retirement preparation, market volatility, and investment strategies.

Product and service1 record
1Oncology Therapeutics Pipeline
CategoryOncology Pharmaceuticals
Description

A portfolio of clinical-stage targeted therapeutics developed for the treatment of cancer patients, addressing unmet needs in oncology through precision drug development. Targeted at biopharmaceutical partners, healthcare providers, and ultimately cancer patients.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Bayer
TypeBroad incumbent
Description

Markets Nubeqa and Xofigo in urologic oncology. Comparable incumbent shaping prostate cancer treatment paradigms.

2Pfizer
TypeBroad incumbent
Description

Global pharma with significant oncology franchise, including prostate cancer assets. Relevant incumbent comparator and potential acquirer profile.

3Astellas Pharma
TypeBroad incumbent
Description

Major pharmaceutical company with a leadership position in urologic oncology (Xtandi). Sets the competitive standard Arno's prostate cancer programs must surpass.

4ESSA Pharma
TypeDirect peer
Description

Clinical-stage biopharma focused on developing treatments for prostate cancer. Highly comparable to Arno Therapeutics given overlapping therapeutic area (urologic oncology), similar development stage, and analogous investor base.

5Veru Inc.
TypeDirect peer
Description

Oncology-focused biopharma with prostate and breast cancer programs, including hormonal therapies. Direct comparator to Arno's onapristone approach in hormone-driven tumors.

6Oncternal Therapeutics
TypeEmerging player
Description

Small-cap clinical-stage oncology company with a pipeline spanning prostate cancer and other solid tumors. Comparable in scale and clinical-stage positioning.

7Tokai Pharmaceuticals
TypeDirect peer
Description

Developed galeterone for castration-resistant prostate cancer. Directly comparable specialty urologic oncology peer that experienced clinical-stage binary outcomes.

8Novartis
TypeBroad incumbent
Description

Major oncology franchise including Pluvicto in prostate cancer. Sets competitive bar and represents potential strategic acquirer of clinical assets.

9Bristol-Myers Squibb
TypeBroad incumbent
Description

Global oncology leader with active prostate cancer and solid tumor programs. Represents both competitive pressure and partnership/acquisition relevance.

10Johnson & Johnson
TypeBroad incumbent
Description

Owns Erleada and historically Zytiga in prostate cancer; broad oncology portfolio. Defines the standard-of-care benchmark Arno would compete against.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arno Therapeutics

Oncology Pharmaceuticalsarnothera.com

Arno Therapeutics is a publicly-traded biopharmaceutical company developing oncology therapeutics for cancer patients, headquartered in Parsippany, New Jersey, with 11-50 employees and a small-cap public listing on OTC pink.

What Arno Therapeutics does

Arno Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic products for the treatment of cancer patients. Founded in 2000 and headquartered in Parsippany, New Jersey, the company operates with a small team of 11-50 employees and trades publicly on the OTC pink market under the ticker ARNI. The company has raised approximately $61.4 million across four disclosed funding rounds between 2010 and 2016, drawing capital from biotech-focused institutional investors including Perceptive Advisors, Soros Fund Management, Pontifax, Bellco Capital, and UTA Capital.

The company's leadership team is anchored by Founder and Co-founder David M. Tanen, who also serves as Secretary and Director, and Chairman of the Board Arie Belldegrun. Historical financial disclosures from 2011-2015 reflect substantial operating losses consistent with a pre-commercial oncology developer, with no revenue line items populated across the disclosed period and EBITDA losses reported each year. The most recent capital activity dates to August 2016, and the company's continued listing on OTC pink (rather than a senior exchange) combined with the absence of post-2016 funding or commercial milestones in the input data suggests limited recent operational momentum.

Note on data quality: A significant portion of the aggregated input describes "Arnothera" (arnothera.com), a privately-operated Gold IRA educational website founded in 2023. This appears to be a distinct entity that has been conflated with Arno Therapeutics in the input. The biopharmaceutical interpretation has been used for this analysis based on the firmographics, leadership, financial, and funding data, which are internally consistent with a small public oncology developer.

Arno Therapeutics firmographics

Firmographics
Name
Arno Therapeutics
Legal name
Arnothera
Website
https://arnothera.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Arno Therapeutics is a publicly-traded biopharmaceutical company developing oncology therapeutics for cancer patients, headquartered in Parsippany, New Jersey, with 11-50 employees and a small-cap public listing on OTC pink.
Ownership category
akta.pro rank

Arno Therapeutics industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
akta.pro secondary industry
Urologic Oncology (HLAKAOAB)

Keywords

  • Oncology drug development
  • Cancer therapeutics
  • Biopharmaceutical products
  • Precision oncology
  • Clinical stage biotech

Where Arno Therapeutics is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Markets served

Arno Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Arno Therapeutics product offering

Product offering

Core offering

Arno Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of cancer patients. The company's work centers on identifying and advancing targeted oncology drug candidates through preclinical and clinical development. Operations are focused on oncology R&D with the goal of addressing unmet medical needs in cancer treatment.

Product overview

Arnothera is a financial information and education company that provides guidance on gold and precious metals IRAs for retirement planning. The core offerings consist of a Gold IRA (Precious Metals IRA) product that enables self-directed retirement accounts holding physical gold, silver, platinum, or palladium, supported by 401(k) to Gold IRA rollover/transfer services. These are complemented by financial education content including articles, worksheets, and guides covering retirement preparation, market volatility, and investment strategies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oncology Therapeutics Pipeline A portfolio of clinical-stage targeted therapeutics developed for the treatment of cancer patients, addressing unmet needs in oncology through precision drug development. Targeted at biopharmaceutical partners, healthcare providers, and ultimately cancer patients.

Companies that use Arno Therapeutics

Customer profile

Segments2 records

Ideal customer profiles1 record

Arno Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Arno Therapeutics partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights1 record

Arno Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Bayer: Markets Nubeqa and Xofigo in urologic oncology. Comparable incumbent shaping prostate cancer treatment paradigms.
  • Pfizer: Global pharma with significant oncology franchise, including prostate cancer assets. Relevant incumbent comparator and potential acquirer profile.
  • Astellas Pharma: Major pharmaceutical company with a leadership position in urologic oncology (Xtandi). Sets the competitive standard Arno's prostate cancer programs must surpass.
  • Novartis: Major oncology franchise including Pluvicto in prostate cancer. Sets competitive bar and represents potential strategic acquirer of clinical assets.
  • Bristol-Myers Squibb: Global oncology leader with active prostate cancer and solid tumor programs. Represents both competitive pressure and partnership/acquisition relevance.
  • Johnson & Johnson: Owns Erleada and historically Zytiga in prostate cancer; broad oncology portfolio. Defines the standard-of-care benchmark Arno would compete against.

Direct peers

  • ESSA Pharma: Clinical-stage biopharma focused on developing treatments for prostate cancer. Highly comparable to Arno Therapeutics given overlapping therapeutic area (urologic oncology), similar development stage, and analogous investor base.
  • Veru Inc. Oncology-focused biopharma with prostate and breast cancer programs, including hormonal therapies. Direct comparator to Arno's onapristone approach in hormone-driven tumors.
  • Tokai Pharmaceuticals: Developed galeterone for castration-resistant prostate cancer. Directly comparable specialty urologic oncology peer that experienced clinical-stage binary outcomes.

Emerging players

  • Oncternal Therapeutics: Small-cap clinical-stage oncology company with a pipeline spanning prostate cancer and other solid tumors. Comparable in scale and clinical-stage positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Arno Therapeutics social profiles

Digital presence

Arno Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arno Therapeutics leadership team

Management profile

Number of profiles

Profiles2 records

Arno Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arno Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arno Therapeutics

What does Arno Therapeutics do?

Arno Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapeutics for the treatment of cancer patients. The company's work centers on identifying and advancing targeted oncology drug candidates through preclinical and clinical development. Operations are focused on oncology R&D with the goal of addressing unmet medical needs in cancer treatment.

Is Arno Therapeutics a public or private company?

Arno Therapeutics is a private company. It is classified as public and is currently operating.

When was Arno Therapeutics founded?

Arno Therapeutics was founded in 2023. It employs 11 to 50 people.

Where is Arno Therapeutics based?

Arno Therapeutics is headquartered in Parsippany, United States, in the North America region.

Who are Arno Therapeutics's main competitors?

Broad incumbents on record are Bayer, Pfizer, Astellas Pharma, Novartis, Bristol-Myers Squibb and Johnson & Johnson. Direct peers are ESSA Pharma, Veru Inc. and Tokai Pharmaceuticals. Oncternal Therapeutics is listed as an emerging player.

Does Arno Therapeutics have an API?

No public API is recorded for Arno Therapeutics.

What industry is Arno Therapeutics in?

Arno Therapeutics's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAKAOAB, Urologic Oncology. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
JiemianThe decline of the Li Feng Mo Er Chinese concept stock leader index has expanded to 1%.The Li Feng Mo Er Chinese concept stock leader index fell 1% to 9161.51 points. Among constituents, Maith Intelligent dropped 12.42%, Zai Ding Pharmaceutical 5.79%, Arno Pharmaceutical 4.7%, AMC Theatres 4.57%, and Longdian Huaxin 4.49%.GlobeNewswireArno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of DrugsArno Therapeutics presented data at ICAAC/ICC 2015 showing AR-12's novel mechanism inhibits chikungunya virus and shows broad-spectrum antifungal activity. The compound, previously in Phase 1 cancer trials, is being evaluated for antiviral and antimicrobial uses, including combination with fluconazole.GlobeNewswireArno Therapeutics to Present at 17th Annual Rodman & Renshaw ConferenceArno Therapeutics CEO Alexander Zukiwski will present at the 17th Annual Rodman & Renshaw Global Investment Conference on September 10, 2015, in New York. The company, focused on oncology therapeutics, has exclusive rights to three anti-cancer product candidates in clinical or preclinical development.GlobeNewswireArno Therapeutics Inc.'s CEO Alexander Zukiwski Interviewed by The Life Sciences ReportArno Therapeutics CEO Alexander Zukiwski discussed its drug pipeline in an interview, highlighting onapristone as an orally available small molecule for cancers and AR-12 as an anti-infective agent. The company positions these compounds to advance through clinical trials and boost investor portfolios.GlobeNewswireArno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive TumorsArno Therapeutics dosed the first patient in the Phase II component of a modified Phase I/II trial evaluating onapristone in women with progesterone receptor positive endometrioid tumors. The study includes up to 29 patients, with enrollment in France ongoing and US sites opening early 2015.GlobeNewswireArno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014Arno Therapeutics will present data on a study evaluating progesterone receptor isotype-specific immunohistochemistry at the 2014 San Antonio Breast Cancer Symposium. The study of 775 breast cancer samples found 60% of ERα-negative, HER2-negative cases were true triple-negative, while 24% were PR-positive with isotype-specific antibodies, suggesting potential for anti-progestin treatment.GlobeNewswireArno Therapeutics' Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics ConferenceArno Therapeutics' David Jackson will present at the 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference in Alexandria, Va., on Oct. 29. He will discuss commercial strategies for companion diagnostic partnerships, including Arno's onapristone program with Leica Biosystems and Clarient Diagnostic Services.GlobeNewswireArno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating OfficerArno Therapeutics appointed Alexander Zukiwski as interim CEO and Lawrence Kenyon as COO, effective immediately. Zukiwski replaces Glenn Mattes, and Kenyon's duties expand to include day-to-day operations. The company will focus on executing its clinical trials for onapristone.GlobeNewswireArno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014Arno Therapeutics announced new data from three research programs supporting its investigational lead compound onapristone for presentation at the AACR Annual Meeting 2014. The studies cover synthesis of radiolabeled onapristone, a pharmacokinetic food effect study, and progesterone receptor isotype-specific immunohistochemistry for triple-negative breast cancer. The company plans to continue clinical trials, including a Phase I trial in women with progesterone-positive solid tumors.GlobeNewswireArno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013Arno Therapeutics will present data on two potential predictive biomarkers at the 2013 San Antonio Breast Cancer Symposium. The study of 397 breast cancer specimens found activated ERα and PR may predict response to anti-estrogen and anti-progestin therapy. The company plans to develop a companion diagnostic for its lead compound onapristone.